REPROS THERAPEUTICS INC's ticker is RPRX and the CUSIP is 76028H209.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $773,000 | +62.4% | 1,171,544 | -21.2% | 0.00% | – |
| Q3 2017 | $476,000 | -32.9% | 1,486,144 | -3.6% | 0.00% | – |
| Q2 2017 | $709,000 | -62.8% | 1,540,844 | -3.0% | 0.00% | – |
| Q1 2017 | $1,906,000 | -13.7% | 1,588,044 | -5.1% | 0.00% | – |
| Q4 2016 | $2,209,000 | -36.8% | 1,673,644 | 0.0% | 0.00% | – |
| Q3 2016 | $3,498,000 | +29.8% | 1,673,644 | 0.0% | 0.00% | – |
| Q2 2016 | $2,695,000 | +21.5% | 1,673,644 | -26.8% | 0.00% | – |
| Q1 2016 | $2,218,000 | -49.7% | 2,286,602 | -37.2% | 0.00% | -100.0% |
| Q4 2015 | $4,406,000 | -83.7% | 3,641,425 | 0.0% | 0.00% | -75.0% |
| Q3 2015 | $27,056,000 | +3.9% | 3,641,425 | 0.0% | 0.00% | +33.3% |
| Q2 2015 | $26,036,000 | -3.6% | 3,641,425 | +15.8% | 0.00% | 0.0% |
| Q1 2015 | $27,017,000 | -10.6% | 3,145,146 | +3.8% | 0.00% | -25.0% |
| Q4 2014 | $30,220,000 | +24.0% | 3,031,056 | +23.2% | 0.00% | +33.3% |
| Q3 2014 | $24,365,000 | +41.6% | 2,461,083 | +147.4% | 0.00% | +50.0% |
| Q2 2014 | $17,212,000 | -5.6% | 994,928 | -3.2% | 0.00% | -33.3% |
| Q1 2014 | $18,239,000 | -0.7% | 1,028,128 | +2.4% | 0.00% | 0.0% |
| Q4 2013 | $18,366,000 | – | 1,003,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 1,001,000 | $970,000 | 0.21% |
| Allegis Investment Advisors, LLC | 341,669 | $331,000 | 0.19% |
| GENERAL AMERICAN INVESTORS CO INC | 396,123 | $384,000 | 0.04% |
| Alambic Investment Management, L.P. | 114,591 | $111,000 | 0.04% |
| Gruss Capital Management LP | 600,000 | $582,000 | 0.02% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 102,086 | $99,000 | 0.01% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 323,429 | $314,000 | 0.01% |
| GSA CAPITAL PARTNERS LLP | 27,931 | $27,000 | 0.00% |
| BENJAMIN F. EDWARDS & COMPANY, INC. | 2,700 | $3,000 | 0.00% |
| Airain ltd | 13,690 | $13,000 | 0.00% |